An updated patent review of AKT inhibitors (2020–present)

L Li, Y Guo, Y Lu, Y Xu, Y Lu, X Zhu… - Expert Opinion on …, 2023 - Taylor & Francis
ABSTRACT Introduction Protein kinase B (Akt), an essential protein in the PI3K/Akt/mTOR
signaling pathway, plays a crucial role in tumor progression. Over the past two years …

An updated patent review of Akt inhibitors (2016-present)

Y Guo, Y Jin, B Qu, Y Zhang, J Che… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: Akt is a widely known serine threonine kinase involved in a series of critical
cellular pathways like cell survival and proliferation. With the development of small-molecule …

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity

E Kostaras, T Kaserer, G Lazaro, SF Heuss… - British Journal of …, 2020 - nature.com
Background AKT, a critical effector of the phosphoinositide 3-kinase (PI3K) signalling
cascade, is an intensely pursued therapeutic target in oncology. Two distinct classes of AKT …

Akt inhibitors in clinical development for the treatment of cancer

SK Pal, K Reckamp, H Yu, RA Figlin - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: The evolution of targeted therapies is dependent upon identification
of cellular moieties that can be pharmacologically modulated. As one such example, the …

Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

ME Mattmann, SL Stoops… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Akt plays a pivotal role in cell survival and proliferation through a number of
downstream effectors; unregulated activation of the PI3K/PTEN/Akt pathway is a prominent …

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use

GM Nitulescu, D Margina… - International …, 2016 - spandidos-publications.com
Targeted cancer therapies are used to inhibit the growth, progression, and metastasis of the
tumor by interfering with specific molecular targets and are currently the focus of anticancer …

Inhibitors of Akt activity

MA Seefeld, MB Rouse, DA Heerding - US Patent 8,273,782, 2012 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
39682107&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Inhibitors of Akt activity

MA Seefeld, MB Rouse, DA Heerding - US Patent 8,410,158, 2013 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
39682107&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Discovery of Inter-Domain Stabilizers A Novel Assay System for Allosteric Akt Inhibitors

Z Fang, JR Simard, D Plenker, HD Nguyen… - ACS Chemical …, 2015 - ACS Publications
In addition to the catalytically active kinase domain, most kinases feature regulatory domains
that govern their activity. Modulating and interfering with these interdomain interactions …

Recent advance of Akt inhibitors in clinical trials

K Guo, W Tang, H Zhuo, G Zhao - ChemistrySelect, 2019 - Wiley Online Library
The serine/threonine kinase Akt, also known as protein kinase B (PKB), exerts a critical role
in the phosphoinositide 3‐kinase (PI3 K)‐Akt signaling pathway that involves in cell growth …